FDA approves treatment for adults with relapsed or refractory acute myeloid leukemia

Author(s):

treatment adults acute myeloid leukemia

On Nov. 28, the FDA approved Xospata (gilteritinib) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia (AML) with a FLT3 mutation as detected by an FDA-approved test.

Read more via U.S. Food & Drug Administration.

LEAVE A REPLY

Please enter your comment!
Please enter your name here